NAB2-STAT6基因融合用于评估血管周细胞瘤/孤立性纤维性肿瘤的原发与转移
本研究从两例多次切除的血管周细胞瘤/孤立性纤维性肿瘤(HPC/SFT)患者的石蜡组织中提取RNA,采用RT-PCR和Archer FusionPlex panel检测NAB2-STAT6融合。两例患者不同时间点的多个肿瘤样本均共享相同的融合断点,提示融合断点检测有助于区分原发与转移。
要点
- NAB2-STAT6融合断点检测可辅助判断HPC/SFT新发病灶为原发或转移。
- 两例患者不同时间点的多个肿瘤样本均显示相同的融合断点。
- RT-PCR和Archer融合 panel 均可用于石蜡组织融合基因检测。
核心结论
- 原发和转移性SFT/HPC在不同时间点共享相同的NAB2-STAT6融合断点。
研究设计与样本
- 从两例多次切除的HPC/SFT患者石蜡组织中提取RNA,采用RT-PCR和Archer FusionPlex panel(94个靶基因)及Illumina NextSeq 550检测融合基因。
主要发现
- 第一例患者HPC后近10年诊断恶性SFT,两者共享相同融合断点。
- 第二例患者脑膜SFT后27年内出现脑和骨/软组织多发病灶,三个病灶共享相同融合断点。
临床怎么用
- 对HPC/SFT新发病灶进行NAB2-STAT6融合断点检测,可辅助鉴别原发与转移。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Hemangiopericytomas (HPCs) and solitary fibrous tumors (SFTs) were considered two distinct entities, but a common gene fusion, NAB2-STAT6, has been identified in both. Although rare, HPCs and SFTs do metastasize, some many years later after resection. Given the extended disease-free interval, it can be difficult to determine with certainty if an HPC or SFT at a new anatomic location represents a second primary or metastatic disease. METHODS: RNA was extracted from formalin-fixed, paraffin-embedded tissue of two patients with multiple SFT/HPC samples. The fusion gene was amplified by reverse transcription polymerase chain reaction (RT-PCR) and a custom-designed Archer FusionPlex panel (94 target genes) and the Illumina NextSeq 550. RESULTS: We identified two patients with multiple resections for HPC/SFT during 26 years at our institution. The first patient had a history of HPC and almost 10 years later she was diagnosed with malignant SFT. The HPC and the SFT shared the same fusion breakpoint. The second patient had multiple lesions in the brain and bone/soft tissue over a 27-year span following a diagnosis of meningeal SFT. Three lesions from this patient shared the same fusion breakpoint. CONCLUSIONS: Our study demonstrated the same fusion breakpoints in primary and metastatic SFTs/HPCs at different time points using both RT-PCR and the Archer fusion panel.
引用
- Singh N, Collingwood R, Eich ML, et al. NAB2-STAT6 Gene Fusions to Evaluate Primary/Metastasis of Hemangiopericytoma/Solitary Fibrous Tumors. Am J Clin Pathol. 2021. PMID: 34075396. doi:10.1093/ajcp/aqab045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。